Alcon Launches Voyager DSLT in the U.S. for First-Line Glaucoma Treatment

Alcon has announced the full U.S. commercial launch of Voyager DSLT, the first and only direct selective laser trabeculoplasty (DSLT) device. This automated laser system simplifies glaucoma treatment workflows, offering precise laser delivery without the need for a gonio lens or manual aiming.

Advancing Laser Therapy for Glaucoma Patients

Designed as a first-line treatment for nearly five million Americans diagnosed with glaucoma, Voyager DSLT features:

       • Automated workflow delivering 120 laser pulses efficiently

       • Intuitive touchscreen interface for ease of use

       • SureTrac eye-tracking technology for precise laser pulse delivery

       • Reduced need for specialized training, increasing accessibility for clinicians

By leveraging advanced laser technology, Voyager DSLT stimulates the eye's natural healing response to improve aqueous outflow and reduce intraocular pressure (IOP).

Medical Community Recognizes the Benefits of SLT

Key medical organizations, including the American Academy of Ophthalmology, recognize selective laser trabeculoplasty (SLT) as an effective first-line treatment for glaucoma. However, manual SLT’s limitations—such as treatment duration and specialized training requirements—have historically restricted access to many clinicians and patients.

"By introducing Voyager DSLT, we’re able to broaden access to first-line SLT therapy and provide eye care professionals with crucial early intervention for their glaucoma patients," said Terry Kim, MD, Chief Medical Officer and Head of Global Medical Safety at Alcon.

Clinical Evidence Supports DSLT’s Efficacy and Safety

A randomized controlled trial confirmed that DSLT provides effective IOP control with a strong safety profile and low risk of adverse events.

Key Findings:

       • 62 percent of DSLT patients were medication-free at 12 months

       • 92.5 percent of DSLT patients would recommend the treatment to others

       • DSLT is positioned to become a widespread first-line intervention for glaucoma

The most common adverse event reported was mild, self-resolving punctate subconjunctival hemorrhage in 20.2 percent of patients, which resolved without clinical sequelae.

Expanding Alcon’s Glaucoma Portfolio

With its launch in the U.S., EU, and UK, Voyager DSLT enhances Alcon’s comprehensive glaucoma portfolio, which includes:

       • Hydrus Microstent

       • EX-PRESS Glaucoma Filtration Device

       • Pharmaceutical eye drops

With Voyager DSLT, Alcon is redefining glaucoma care, making laser therapy more accessible, efficient, and effective for patients and clinicians alike.

References:

     1. Alcon announces U.S. launch of Voyager DSLT, first-of-its-kind treatment for glaucoma and ocular hypertension. News release. Alcon. February 19, 2025. Accessed February 19, 2025. https://www.alcon.com/media-release/alcon-announces-us-launch-voyager-dslt-first-its-kind-treatment-glaucoma-and-ocular/

     2. Ehrlich JR, Burke-Conte Z, Wittenborn JS, et al. Prevalence of glaucoma among US adults in 2022. JAMA Ophthalmol. 2024;142(11):1046-1053. doi:10.1001/jamaophthalmol.2024.3884

     3. Voyager DSLT User Guide; 2024.

     4. GLAUrious Study - Clinical Study Report (CSR). CA-RP-01-006, Rev. 01; 2022.

     5. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Laser in glaucoma and ocular hypertension (LiGHT) trial: six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology. 2023;130(2):139-151. doi:10.1016/j.ophtha.2022.09.009

     6. Takusagawa HL, Hoguet A, Sit AJ, et al. Selective laser trabeculoplasty for the treatment of glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2024;131(1):37-47. doi:10.1016/j.ophtha.2023.07.029

     7. European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021;105(Suppl 1):1-169. doi:10.1136/bjophthalmol-2021-egsguidelines

     8. National Institute for Health and Care Excellence. Glaucoma: Diagnosis and Management. London: National Institute for Health and Care Excellence (NICE); 2022.

     9. Alcon Data on File, 2024.